Acting Chief Scientific Officer · Cullinan Therapeutics, Inc. (CGEM)

Patrick Baeuerle

A named executive officer of Cullinan Therapeutics in every fiscal year CompBrief holds from FY2020 to FY2021. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2021

$4,675,977

Salary $450,000Bonus $218,000

FY2020: $5,353,496

3rd of 4 named executive officers at Cullinan Therapeutics by FY2021 total.

4 named officers on file for Cullinan Therapeutics, FY2021

Patrick Baeuerle’s pay file — $29

  • 2 fiscal years of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Cullinan Therapeutics’s whole pay program stands against its peers

  • Cullinan Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on CGEM→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 29, 2022 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Patrick Baeuerle’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Patrick Baeuerle compensation by year

Cullinan Therapeutics Summary Compensation Table · all 2 fiscal years held
In US dollars, as Cullinan Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2020FY2021
Salary$436,997$450,000
Bonus$266,131$218,000
Stock awards$491,284—
Option awards$4,124,284$3,973,177
All other$34,800$34,800
Total$5,353,496$4,675,977

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Cullinan Therapeutics, Inc. DEF 14A filed April 29, 2022, accession 0001193125-22-130030, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Cullinan Therapeutics, Inc. filed document, accession 0001193125-22-130030. Every figure is read from that document and cited to the page and table it appears in. Filed April 29, 2022.

$5.4M
$4.7M
FY20
FY21
SalaryBonusStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2021 year-end
TypeUnvested unitsValue at year-endExercise price
RSU8,366$129,087—
RSU7,805$120,431—
RSU5,547$85,590—
Option49,147—$4.30
Option286,665—$21.00
Option144,498—$4.30

Per the Outstanding Equity Awards at Fiscal Year-End table in Cullinan Therapeutics, Inc.'s FY2021 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

2 Form 4 lines since the FY2021 proxy (filed April 29, 2022)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2023-02-17Grant or award derivative—77,000$0.0077,000
2023-02-17Grant or award—38,500$0.0076,000

The 2 most recent of 2 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Cullinan Therapeutics’s named executive officers, FY2021

as the company reported each
Named executive officerRoleFY2021 total
Nadim AhmedPresident and Chief Executive Officer$38,547,200
Owen HughesFormer President and Chief Executive Officer$6,786,187
Patrick Baeuerle · this pageActing Chief Scientific Officer, Biologics$4,675,977
Jeffrey TrigilioChief Financial Officer$2,667,277

The full Cullinan Therapeutics compensation record

free company brief

This page is one person within Cullinan Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Cullinan Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Patrick Baeuerle's compensation dossier · One-time report. No refunds.